Publications by authors named "E Maffini"
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome.
Haematologica
December 2024
Article Synopsis
- Plasma metabolomics analysis was conducted on 44 patients with relapsed/refractory B-cell non-Hodgkin lymphoma who were treated with CD19.CAR-T cell therapy, examining various time points before and after treatment.
- At pre-lymphodepletion, a specific metabolic profile indicated poor outcomes, with high levels of lipoproteins and lactate linked to elevated lactate dehydrogenase.
- By day 30, two patient clusters were identified: one group experienced long-term remission, while the other, with higher N-GlycA levels, was prone to relapse within a year, suggesting that pro-inflammatory shifts may be associated with relapse risk.
BACKGROUNDPredicting immune effector cell-associated neurotoxicity syndrome (ICANS) in patients infused with CAR T cells is still a conundrum. This complication, thought to be consequent to CAR T cell activation, arises a few days after infusion, when circulating CAR T cells are scarce and specific CAR T cell-derived biomarkers are lacking.METHODSCAR+ extracellular vesicle (CAR+EV) release was assessed in human CD19.
View Article and Find Full Text PDFEvaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Transplant Cell Ther
June 2024
Sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease (VOD), is a rare but potentially fatal complication following allogenic hematopoietic cell transplantation (allo-HCT). Timely identification of SOS/VOD to allow for prompt treatment is critical, but identifying a VOD-predictive biomarker remains challenging. Given the pivotal role of endothelial dysfunction in SOS/VOD pathophysiology, the CECinVOD study prospectively evaluated levels of circulating endothelial cells (CECs) in patients undergoing allo-HCT with a myeloablative conditioning (MAC) regimen to investigate the potential of CEC level in predicting and diagnosing SOS/VOD.
View Article and Find Full Text PDF